ARCHIVES

FDA Approves Xeloda For Colon Cancer; Phase III Data Not Reviewed By ODAC.

This article is from The Cancer Letter archive.

Vol. 27 No. 18 | May 4, 2001

Download PDF Visit The Full Archive

Related Articles

Senate Passes NIH Reauthorization 87-10; $2.5 Bil. Auhtority For NCI, New Line Items

April 10, 1992

In Brief: NCI Recieves Two Proposals For Antineoplaston Trials, None For Children; Stubble Elected To NAS

June 19, 1992

ODAC Rejects Amsacrine NDA, Renews Idarubicin

September 14, 1990

FDA Approves Iressa For Third-Line Treatment Of Non-Small Cell Lung Cancer

May 9, 2003

Seventeen New ACS-Roosevelt Grants Awarded

July 25, 1975

Preliminary Action Plan Seeks Consumer Representation

January 7, 1994